With the recently approved rheumatoid arthritis therapies along with new therapies are sure to drive the rheumatoid arthritis therapeutics market in Asia-Pacific . The promising pipeline companies are Johnson & Johnson ( J & J ), GlaxoSmithKline ( GSK )' s sirukumab , and Galapagos ' s filgotinib . The leading players in rheumatoid arthritis therapeutics market are AbbVie , Amgen , Amgen , Daiichi Sankyo , Biogen Idec , Genentech , Bristol-Myers Squibb , Eli Lilly , Johnson & Johnson , Merck , Pfizer , Regeneron , Sanofi , Roche and UCB .
India , Australia , China , South Korea and Japan are the leading consumers in Asia-Pacific ( APAC ) rheumatoid arthritis therapeutics market . Japan accounted for a majority share of the market , followed by China , Australia , India and South Korea . The introduction of biologic disease modifying antirheumatic drugs ( DMARD ) has helped in the growth of the rheumatoid arthritis ( RA ) market in Asia-Pacific tremendously over the last two decades . This growth is expected to continue at a moderate pace in the next few years .
To know more , click on the link below :
https :// www . kenresearch . com / healthcare / general-healthcare / rheumatoid-arthritistherapeutics-in-asia-pacific-markets-to-2023-novel-jak-and-il-6-receptor-inhibitors-tostimulate-moderate-growth-despite-launch-of-biosimilars-of-blockbuster-anti-tnfs / 149110- 91 . html
Related Reports :
https :// www . kenresearch . com / healthcare / general-healthcare / osteoarthritis-pipelinereview / 143930-91 . html
https :// www . kenresearch . com / healthcare / pharmaceuticals / osteoarthritis-pipeline-reviewh2-2017 / 142124-91 . html
Contact Us : Ken Research Ankur Gupta , Head Marketing & Communications sales @ kenresearch . com 0124-4230204